Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China
文献类型：期刊论文
| 作者 | Shi, Yuequan10; Fang, Jian11; Zhou, Chengzhi12; Liu, Anwen13; Wang, Yan14; Meng, Qingwei15; Ding, Cuimin16; Ai, Bin17; Gu, Yangchun18; Yao, Yu19 |
| 刊名 | THORACIC CANCER
 |
| 出版日期 | 2021-12-21 |
| ISSN号 | 1759-7706 |
| 关键词 | advanced lung cancer immune checkpoint inhibitors immune-related adverse events real-world data |
| DOI | 10.1111/1759-7714.14274 |
| 通讯作者 | Wang, Mengzhao(mengzhaowang@sina.com) |
| 英文摘要 | Background Immune checkpoint inhibitors (ICIs) are the standard treatment for advanced lung cancer, but immune-related adverse events (irAEs) remain poorly understood, especially in a real-world setting. Methods A multicenter observational study was conducted. Medical records of lung cancer patients treated with ICIs at 26 hospitals from January 1, 2015, to February 28, 2021, were retrieved. Types of ICIs included antiprogrammed cell death 1 or antiprogrammed cell death ligand 1 (PD-L1) monotherapy, anticytotoxic T-lymphocyte antigen-4 monotherapy, or combination therapy. Results In total, 1905 patients with advanced lung cancer were evaluated. The median age was 63 (range 28-87) years, and the male/female ratio was 3.1:1 (1442/463). The primary histological subtype was adenocarcinoma (915). A total of 26.9% (512/1905) of the patients developed 671 irAEs, and 5.8% (110/1905) developed 120 grade 3-5 irAEs. Median duration from ICI initiation to irAEs onset was 56 (range 0-1160) days. The most common irAEs were thyroid dysfunction (7.2%, 138/1905), pneumonitis (6.5%, 124/1905), and dermatological toxicities (6.0%, 115/1905). A total of 162 irAEs were treated with steroids and 11 irAEs led to death. Patients with positive PD-L1 expression (>= 1%) and who received first-line ICI treatment developed more irAEs. Patients who developed irAEs had a better disease control rate (DCR, 71.3% [365/512] vs. 56.0% [780/1145]; p < 0.001). Conclusions The incidence rate of irAEs was 26.9% in a real-world setting. IrAEs might be related to a better DCR, but clinicians should be more aware of irAE recognition and management in clinical practice. |
| WOS关键词 | EFFICACY ; PEMBROLIZUMAB ; IMMUNOTHERAPY ; CHEMOTHERAPY ; NIVOLUMAB ; OUTCOMES |
| 资助项目 | Merk Co., Ltd. |
| WOS研究方向 | Oncology ; Respiratory System |
| 语种 | 英语 |
| 出版者 | WILEY |
| WOS记录号 | WOS:000732478600001 |
| 资助机构 | Merk Co., Ltd. |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/126988]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 通讯作者 | Wang, Mengzhao |
| 作者单位 | 1.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Med Oncol, Hangzhou, Peoples R China 2.Shanxi Prov Canc Hosp, Dept Resp Med, Taiyuan, Peoples R China 3.Fudan Univ, Dept Med Oncol, Zhongshan Hosp, Shanghai, Peoples R China 4.Quzhou Peoples Hosp, Dept Resp & Crit Care Med, Quzhou, Zhejiang, Peoples R China 5.Zhejiang Prov Peoples Hosp, Dept Resp Med, Hangzhou, Zhejiang, Peoples R China 6.Zhejiang Univ, Affiliated Zhejiang Hosp, Dept Resp Med, Sch Med, Hangzhou, Zhejiang, Peoples R China 7.Zhuji Peoples Hosp, Dept Resp Med & Crit Care Med, Zhuji, Zhejiang, Peoples R China 8.Shanghai Jiao Tong Univ, Renji Hosp, Dept Oncol, Sch Med, Shanghai, Peoples R China 9.Zhejiang Univ, Affiliated Hosp 2, Dept Radiat Oncol, Sch Med, Hangzhou, Peoples R China 10.Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Resp & Crit Care Med, Beijing 100730, Peoples R China |
| 推荐引用方式 GB/T 7714 | Shi, Yuequan,Fang, Jian,Zhou, Chengzhi,et al. Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China[J]. THORACIC CANCER,2021. |
| APA | Shi, Yuequan.,Fang, Jian.,Zhou, Chengzhi.,Liu, Anwen.,Wang, Yan.,...&Wang, Mengzhao.(2021).Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China.THORACIC CANCER. |
| MLA | Shi, Yuequan,et al."Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China".THORACIC CANCER (2021). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。